An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
Kura Oncology said that it intends to enroll more patients for a registration-directed Phase II trial in 2020 following positive FDA feedback.
Olaparib is the first PARP inhibitor approved in China for first-line maintenance treatment of germline and somatic BRCA mutated gynecological cancers.
The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The company is enrolling up to 400 patients in its LIBRETTO-431 trial to evaluate survival and response to selpercatinib.